Proprietary technology identifies small molecule JAK2 and Pim kinase
SAN FRANCISCO, Oct. 25 /PRNewswire-FirstCall/ -- SuperGen Inc. (Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies, today announced data as part of a series of presentations at the 2007 AACR-NCI-EORTC International Conference that describe how its proprietary CLIMB technology was used in lead development and design of small molecule JAK2 and Pim kinase inhibitors (Posters C200 and C208).
Poster C200 (Abstract No. 907)
Effect of small molecule inhibitors of JAK2 kinase on modulating signaling cascades downstream of cytokine receptors
Janus kinases (JAKs) are critical to a number of intracellular signaling pathways. Dysregulation of JAK2 signaling has been implicated in myoproliferative disorders, leukemia, lymphoma and various solid tumors. Utilizing CLIMB, SuperGen's proprietary technology, scientists used a JAK2 crystal structure to build several models that were made into a substrate for screening a large, virtual small molecule library. This process generated a subset of leads that were screened using in silico algorithms to identify "druggable" candidates to pursue.
Poster C208 (Abstract No. 985)
A small molecule inhibitor of Pim-1 kinase with activity in both hematological and solid tumor malignancies
Pim-1 kinase is involved in signaling pathways as a potent inhibitor of
programmed cell death (apoptosis). Pim-1 is over expressed in many cancer
types, including AML, CML, bladder and oral cancers. Scientists used
SuperGen's CLIMB technology to build a model that allowed for the
prediction of small molecule inhibitors. Leads were screened to identify
those with inhibitory activity with low nanomolar IC50 concentrations. Data
support further development of the lead compounds in liquid a
|SOURCE SuperGen Inc.|
Copyright©2007 PR Newswire.
All rights reserved